---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018036"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:41:55.266693+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PAVmed subsidiary Lucid Diagnostics raises $11.6M in Series B-1 preferred stock offering

## Summary
- Lucid Diagnostics, PAVmed's majority-owned subsidiary, raised ~$11.6M via Series B-1 Convertible Preferred Stock.
- Sold approx 11,634 shares at $1,000/share to accredited investors; closed May 6, 2024.
- Lucid filed Certificate of Designation for Series B-1 Preferred and entered Registration Rights Agreement.
- Details are incorporated by reference from Lucid Diagnostics' separate 8-K filed May 7, 2024.

## SEC filing metadata
- accession: 0001493152-24-018036
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315224018036/0001493152-24-018036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315224018036/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018036
- JSON: https://secwatch.observer/filing/0001493152-24-018036.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018036.txt

## Key facts
- Material Agreements
  PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at approximately $11.6 million (effective 2024-05-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $11.6 million
  - Effective: 2024-05-01
  source text: entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors (collectively, the “ Investors ”), which agreements provided for the sale to the Investors of approximately 11,634 shares of Lucid Diagnostics’ newly designated Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), at a purchase price of $1,000 per share (collectively, the “ Offering ”). The gross proceeds to Lucid Diagnostics of the Offering were approximately $11.6 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315224018036/0001493152-24-018036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.